Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants

In June 2010, Greece introduced the 13-valent pneumococcal conjugate vaccine (PCV13) for pediatric vaccination and has since observed a large decrease in pneumococcal disease caused by these vaccine serotypes, yet the disease prevalence of non-vaccine serotypes has increased. Two higher-valent conju...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Sophie, Barmpouni, Myrto, Kossyvaki, Vasiliki, Gourzoulidis, George, Perdrizet, Johnna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459953/
https://www.ncbi.nlm.nih.gov/pubmed/37631937
http://dx.doi.org/10.3390/vaccines11081369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459953/
https://www.ncbi.nlm.nih.gov/pubmed/37631937
http://dx.doi.org/10.3390/vaccines11081369

Ejemplares similares